Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium
about
Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot"Estrogen receptor beta and ovarian cancer: a key to pathogenesis and response to therapyGenetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancerAssociation between DNA damage response and repair genes and risk of invasive serous ovarian cancer.Studies on Xenopus laevis intestine reveal biological pathways underlying vertebrate gut adaptation from embryo to adultA genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.Analyzing association of the XRCC3 gene polymorphism with ovarian cancer risk.ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study.Relevance of DNA repair gene polymorphisms to gastric cancer risk and phenotypePolymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium.Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium.Relevance of LIG4 gene polymorphisms with cancer susceptibility: evidence from a meta-analysisGenetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association ConsortiumEstrogen biosynthesis and action in ovarian cancer.Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen.The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testingGenomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer.The new face of ovarian cancer modeling: better prospects for detection and treatment.Assessment of genetic mutations in the XRCC2 coding region by high resolution melting curve analysis and the risk of differentiated thyroid carcinoma in Iran.ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association ConsortiumOvarian cancer and DNA repair: DNA ligase IV as a potential key.Genetics and women's health issues--the commitment of EMS to women scientists and gender-associated disease topics.Genetic variants in XRCC2: new insights into colorectal cancer tumorigenesisPolymorphisms in TCEAL7 and risk of epithelial ovarian cancershRNA-mediated XRCC2 gene knockdown efficiently sensitizes colon tumor cells to X-ray irradiation in vitro and in vivo.Associations between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and ovarian cancerDNA repair: the link between primary immunodeficiency and cancer.Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers.Primary culture and immortalization of human fallopian tube secretory epithelial cells.XRCC2 R188H (rs3218536), XRCC3 T241M (rs861539) and R243H (rs77381814) single nucleotide polymorphisms in cervical cancer risk.Haplotype analysis of XRCC2 gene polymorphisms and association with increased risk of head and neck cancer.Patterns of pharmacogenetic diversity in African populations: role of ancient and recent history.Role of DNA repair and cell cycle control genes in ovarian cancer susceptibility.Polymorphisms in CYP1A1 and CYP3A5 Genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting.Polymorphisms of homologous recombination RAD51, RAD51B, XRCC2, and XRCC3 genes and the risk of prostate cancer.DNA damage repair in ovarian cancer: unlocking the heterogeneity.
P2860
Q21144976-14436DBA-E6ED-4025-B07A-1721F9A8545AQ28109453-90A3F2F0-9FAE-403C-8554-0DF4E7E6E0CDQ33422082-E138B537-06ED-4C25-9DC7-7ED2B5DF2F00Q33553322-79DEB7A4-906F-4B46-8BB4-22216B103C2CQ33581414-05DDF30F-1F85-46AE-B82E-7D2EF7E71746Q33747778-8CFC1679-BDCB-4A24-804A-1B59DF26E1FBQ33810401-C4437182-F0F2-4484-8C90-06AB27E3E0C4Q33824208-AAB0306D-49C5-4E08-B263-DDA32493AD43Q33829340-0372E0C1-31AB-4774-ABD0-38EBD377FA47Q33891803-AA1468D6-D50B-42DF-8D91-778C8040D88EQ33932856-2ACC90B5-919B-4740-AFAD-AD9B95841201Q34340919-3E8D6510-8793-44E1-8E6B-B813CC68BF0BQ34453723-47EDDE84-619D-4DFD-82D9-3C2892FC7BC2Q34496401-257302F6-7B27-40A9-8508-3D082C1AD319Q34860928-1DB5E6F2-C50B-4BA0-AF43-21626B51770CQ35024008-DDC5B7B0-F68D-4F66-9AA6-1909A6C0329FQ35058278-714390B2-0962-4638-8D78-18FDE1AE7E08Q35507860-37521649-1870-46AD-A515-EBA3FA31EE8EQ35855423-85FCA0C4-2B3B-4FBD-8921-BAA0A44160A3Q36327057-93AB7945-859A-413E-B5F3-D47F64B1E371Q36718896-847756AE-C2A8-4FA4-B3D3-1DC4B55F429DQ37074094-0B7853F6-0273-4C67-BA79-ED87A633D520Q37343499-F01B1693-8383-41BC-A371-7203A67C8CF1Q37378586-4256477C-854F-418C-908A-F98ADC3E0929Q37645154-4AA9F9C4-3DA9-4EB3-BDDD-69B5FCA01FDAQ37699301-748694F2-32DA-4272-9C62-3221FFA5FF4CQ37974984-40D1F17D-3C56-43EE-8033-6DE000BCD9BFQ39219310-98684372-6214-4507-A151-CDE0E32FE21BQ39287947-73BF2776-3284-49A2-B0D3-408A93212C3FQ39443419-17C738C8-313E-45CB-85A9-96B17F92F149Q42378954-80C2CACB-3E5B-4881-8DD8-6FE54793BF71Q42634060-7E02B5EC-A250-487E-9801-77710EA5F5F0Q46641639-D0155D79-27ED-4D6B-860A-140D8F7D0C82Q51347270-AA3116C9-620C-41E1-931B-4A624BDB9790Q54877659-0E8768C3-A96E-481C-934D-E3140359BD20Q55399645-4A8F0C3C-6527-4261-BA56-57BB7B668D6F
P2860
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Validating genetic risk associ ...... Cancer Association Consortium
@en
Validating genetic risk associ ...... Cancer Association Consortium.
@nl
type
label
Validating genetic risk associ ...... Cancer Association Consortium
@en
Validating genetic risk associ ...... Cancer Association Consortium.
@nl
prefLabel
Validating genetic risk associ ...... Cancer Association Consortium
@en
Validating genetic risk associ ...... Cancer Association Consortium.
@nl
P2093
P2860
P50
P356
P1476
Validating genetic risk associ ...... Cancer Association Consortium
@en
P2093
A Berchuck
A F Vitonis
A R Anderson
A S Whittemore
Australian Cancer Study
C K Edlund
C K Hogdall
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604820
P407
P50
P577
2009-01-06T00:00:00Z
P5875
P6179
1049927140